

FINAL PROGRAM



PARTNERS

The Organizing Committee would like to express its gratitude to all institutions and companies that have supported the State-of-the-Art Congress in Gynecologic Oncology (SAGO 2025)

MAIN PARTNERS

abbyie





PARTNERS





LANYARD PARTNER



SUPPORTER



ORGANIZED BY

COMPLIANCE







SAGO PROGRAM

TABLE OF CONTENT

FLOOR PLAN	4
CONFERENCE INFORMATION	4
SCIENTIFIC PROGRAM	
SEPTEMBER 29, 2025 (MONDAY)	7
SEPTEMBER 30, 2025 (TUESDAY)	9
E-POSTERS	11
LIST OF DECOMMENDED DESTALIDANTS CLOSE TO THE VENUE	17



MOBILE APPLICATION NAME: SAGO2025







CONFERENCE PLATFORM

TO ACCESS THE PLATFORM, PLEASE CLICK THE "USER LOGIN" LINK IN THE TOP RIGHT CORNER OF THE PAGE.




NAME: SAGO2025

PASSWORD: 20SA_GO25

FLOOR PLAN

The main program is held in the Prague Halls A-D located at the second floor. The exhibition area is held in the foyer of Prague Halls A-D.



CONFERENCE INFORMATION

CONFERENCE VENUE

Vienna House by Wyndham Diplomat Prague

The 4-star Vienna House by Wyndham Diplomat Prague is easily and comfortably reached by car as well as by public transport. The Václav Havel Airport Prague can be reached quickly and easily via a direct bus connection.

Address: Evropská 15, 160 41 Prague 6, Czech Republic



INTERNET ACCESS

Free of charge Wi-Fi connection will be available in all conference and exhibition area.

Network Name: SAGO2025 Password: 20SA_GO25

REGISTRATION DESK

The registration desk is located on the first floor of Vienna House by Wyndham Diplomat Prague.

REGISTRATION OPENING HOURS

Monday, September 29, 2025 07:00 - 18:30 Tuesday, September 30, 2025 07:30 - 17:00

SELF-CHECK-IN

On-site registration and badge collection will be facilitated through self-check-in kiosks at the venue.

You will receive a QR code via email prior to the conference. Print the QR code or use your mobile device to obtain your badge.

NAME BADGE

All delegates will receive a name badge upon registration. Everyone is kindly requested to wear his/her badge when attending the conference.

Each badge contains a unique QR code, which includes the participant's ID. Therefore, please remember to always bring your badge with you.

Participants may allow exhibitors to scan their QR code using a QR code reader provided by the organizers when visiting the exhibition. This scan allows exhibitors to collect relevant information.

The scanning of QR codes by exhibitors is conducted based on the consent provided by the participant.

Organizers will securely manage and provide the list of scanned delegates to exhibitors after the conference.

Please note that there will be a 30 EUR charge to replace lost badges.

MOBILE APPLICATION

Name: SAGO 2025

With access to the online mobile app you will have the opportunity to increase your interactivity during the conference.









CONFERENCE PLATFORM

The conference platform allows you to complete the evaluation form, view e-posters, access conference presentations (available two weeks after the event), and download your certificate of attendance.

To access the platform, please visit https://sago2025.gcon.me/ and click the "User Login" link in the top right corner of the page. You will be prompted to enter your login credentials (email address and password).

If this is your first time logging in, enter the email address you used during registration. A password will be sent to that email.

If you do not receive the email, please check your spam or junk folder.



E-POSTERS

E-posters are accessible through the Program section of the mobile application, and are also available on the conference platform at https://sago2025.gcon.me/.

The Best Abstract Session is scheduled to take place on September 29, 2025, from 14:10-14:25.

CONFERENCE PRESENTATIONS

Presentations from the conference will be available on the conference platform two weeks after the event.

Please note that access to the recordings will be available for six months and is intended for viewing only — downloading will not be possible.

REFRESHMENTS

Complimentary coffee breaks will be provided for all registered participants in the exhibition area.

LUNCHES

Please note that lunch is not included in the standard conference registration.

For participants who have purchased lunch in advance, it will be served in the Loreta Restaurant, located on the same floor as the main conference halls. Kindly follow the directional signage.

Additional lunch tickets may be purchased at the registration desk by 10:00 AM on both conference days.

Price: EUR 27 per day.

FITNESS BREAKS

A short 3-5 minute fitness break will take place between presentations - a light full-body stretch to keep you refreshed and energised throughout the day.

EVALUATION FORM


To help us improve the program and overall concept of future SAGO conferences according to your needs, we kindly ask you to complete the evaluation form.

The evaluation form is available on the conference platform at https://sago2025.gcon.me/.

Please refer to the Conference Platform section above for detailed login instructions.

CERTIFICATE OF ATTENDANCE

To obtain your certificate of attendance, kindly access the conference platform at https://sago2025.gcon.me/ and download the certificate from the designated section.



SCIENTIFIC PROGRAM

SEPTEMBER 29, 2025 (MONDAY)

08:00-08:15	Welcome message David Cibula (Czech Republic)	
08:15-10:20	Diagnostics and staging Chairs: Daniela Fischerova (Czech Republic), Lukas Lambert (Czech Republic)	
08:15-08:45	Rational use of imaging methods in gynaecological oncology Daniela Fischerova (Czech Republic), Lukas Lambert (Czech Republic), Sona Balogova (Slovakia)	
08:45-09:00	9:00 Preoperative staging of pelvic masses Daniela Fischerova (Czech Republic)	
09:00-09:30	Assessment of lymph nodes by US, PET and MRI Filip Fruhauf (Czech Republic), Lukas Lambert (Czech Republic), Sona Balogova (Slovakia)	
09:30-09:35	Fitness break	
09:35-09:50	Pelvic side wall anatomy and assessment Gabor Szabo (Hungary)	
09:50-10:05	Imaging guided procedures Maciej Stukan (Poland)	
10:05-10:20		
10:20-10:45		
10:45-12:10	Systemic treatment of ovarian cancer in the first line Chairs: David Cibula (Czech Republic), Pavel Dundr (Czech Republic)	
10:45-11:00	What is BRCA, HRD, HRR, and how they are tested Pavel Dundr (Czech Republic)	
11:00-11:15	Biomarkers in ovarian cancer - which and when Vit Weinberger (Czech Republic)	
11:15-11:20	Fitness break	
11:20-11:35	Current SoA chemotherapy Radoslaw Madry (Poland)	
11:35-11:50	Maintenance treatment in 1L and beyond David Cibula (Czech Republic)	
11:50-12:10	Discussion	
12:10-13:10	Lunch break	
13:10-14:10	Live ultrasound scanning Daniela Fischerova (Czech Republic), Filip Fruhauf (Czech Republic)	
14:10-14:25	Best abstract session Chairs: Michal Zikan (Czech Republic), David Cibula (Czech Republic)	

SAGO PROGRAM 7

14:25-16:00	Surgical treatment in early stages Chairs: Michal Zikan (Czech Republic), David Cibula (Czech Republic)	
14:25-14:45	Surgical treatment of early stage cervical cancer in the "after SHAPE" era David Cibula (Czech Republic)	
14:45-15:00	Surgical treatment of non-epithelial and other rare ovarian tumors Michal Zikan (Czech Republic)	
15:00-15:05	Fitness break	
15:05-15:25	Sentinel lymph node biopsy in gynaecological cancers David Cibula (Czech Republic)	
15:25-15:40	Management of patients with micrometastases and isolated tumor cells in SLN Roman Kocian (Czech Republic)	
15:40-16:00	Discussion	
16:00-16:25	Coffee break	
16:25-17:50	Platinum resistant recurrent ovarian cancer (PROC) Chairs: Toon van Gorp (Belgium), David Cibula (Czech Republic)	
16:25-16:40	Current SoA treatment of PROC Toon van Gorp (Belgium)	
16:40-16:55	Predictive biomarkers and their testing Pavel Dundr (Czech Republic)	
16:55-17:05	What is ADC and how it works Toon van Gorp (Belgium)	
17:05-17:15	First ADC approved in ovarian cancer in Europe David Cibula (Czech Republic)	
17:15-17:30	Challenging management of new types of adverse events Sajjad Ahmad (United Kingdom)	
17:30-17:45	Discussion	
17:45-17:50	Fitness break	FITNESS BREAK
17:50-18:50	Fertility sparing treatment and cancer in pregnancy Chairs: Jiri Slama (Czech Republic), Michael Halaska (Czech Republic)	
17:50-18:05	Fertility preservation in cervical cancer Jiri Slama (Czech Republic)	
18:05-18:20	Fertility preservation in endometrial cancer Mikulas Redecha (Slovakia)	
18:20-18:35	Management of gynaecological tumors in pregnancy Michael Halaska (Czech Republic)	
18:35-18:50	Discussion	

SEPTEMBER 30, 2025 (TUESDAY)

	SEFTEINDER 30, 2023 (TOESDAT)	
08:00-09:05	Endometrial cancer Chairs: Ales Ryska (Czech Republic), Toon van Gorp (Belgium)	
08:00-08:15	Molecular classification in endometrial cancer for beginners Ales Ryska (Czech Republic)	
08:15-08:30	Indications of adjuvant treatment in the molecular era Igor Sirak (Czech Republic)	
08:30-08:45	Systemic treatment of metastatic and recurrent endometrial cancer Toon van Gorp (Belgium)	
08:45-09:00	00 Discussion	
09:00-09:05	Fitness break	
09:05-10:05	Surgical treatment in advanced stages Chairs: Zoltan Novak (Hungary), Nicolò Bizzarri (Italy)	
09:05-09:25	Secondary cytoreduction in ovarian and endometrial cancer Zoltan Novak (Hungary)	
09:25-09:40	Pelvic exenteration Nicolò Bizzarri (Italy)	
09:40-09:50	LEER and out-of-box procedures Vito Chiantera (Italy)	
09:50-10:05	Discussion	
10:05-10:30	Coffee break	
10:30-12:05	Perioperative and palliative care Chairs: Sara Nasser (Italy/Germany), Maja Pakiz (Slovenia)	
10:30-10:50	Implementation of ERAS and prehabilitation into the routine practice Maja Pakiz (Slovenia)	
10:50-11:10	Early palliative care and best supportive care in gynaecological oncology Sara Nasser (Italy/Germany)	
11:10-11:15	Fitness break	
11:15-11:45	Communicating serious news effectively: Tips and tricks for a person-centred approach Katerina Rusinova (Czech Republic)	
11:45-12:05	Discussion	



12:05-13:05 *Lunch break*

13:05-14:25	Management of locally advanced and metastatic cervical cancer Chairs: Igor Sirak (Czech Republic), David Cibula (Czech Republic)	
13:05-13:15	Chaos in classification (intermediate/ high risk, IB3, locally advanced disease, FIGO 2014 vs 2018) David Cibula (Czech Republic)	
13:15-13:35	What is the current standard in locally advanced cervical cancer (chemoradiotherapy vs induction chemotherapy vs immunotherapy) Igor Sirak (Czech Republic)	
13:35-13:55	First line treatment of metastatic disease Pawel Blecharz (Poland)	
13:55-14:05	How to manage toxicity and enhance treatment compliance Assia Konsoulova (Bulgaria)	
14:05-14:25	Discussion	
14:25-15:30	Video session - Key steps in key surgical procedures visualized Chairs: Alessandro Buda (Italy), Michael Halaska (Czech Republic)	
14:25-14:40	Paraaortic lymphadenectomy (MIS) Alessandro Buda (Italy)	
14:40-14:55	Nerve sparing radical hysterectomy (MIS) Andreas N. Kavallaris (Greece)	
14:55-15:00	Fitness break	
15:00-15:15	Radical hysterectomy (open) Michael Halaska (Czech Republic)	
15:15-15:30	Pelvic LN staging Maciej W. Socha (Poland)	
15:30-15:55	Coffee break	
15:55-17:15	Immunotherapy and endocrine treatment Chairs: Jitka Fucikova (Czech Republic), Ludmila Krizova (Czech Republic)	
15:55-16:10	A guide to cancer immunotherapy Radek Spisek (Czech Republic)	
16:10-16:25	Principles of cancer immunotherapy strategies Jitka Fucikova (Czech Republic)	
16:25-16:40	Endocrine treatment in gynaecological tumors Jiri Presl (Czech Republic)	
16:40-16:55	The role of NGS and molecular tumor boards in current management Ludmila Krizova (Czech Republic)	
16:55-17:15	Discussion	

E-POSTERS

id	topic	title
1	Miscellaneous	Thirty-Year Trends in Malignant Uterine Corpus Neoplasms Among Reproductive-Age Women in Belarus (1993–2022): A Population-Based Registry Study Olga Matylevich
2	Surgical treatment	The significance of a positive surgical margin for a high-grade precursor lesion in the treatment of vulvar precancers Martin Janošík
3	Surgical treatment	The Role of Laparoscopic Hysterectomy in Endometrial Cancer in Kidney Transplant Recipients Aliaksandr Varenik
4	Surgical treatment	Clinical Effectiveness of Primary Cytoreduction in Patients with Ovarian Cancer Aliaksandr Varenik
5	Systemic treatment	Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: first experience in safety and efficacy from Belarus Hanna Trukhan
6	Miscellaneous	Extraovarian Sertoli cell tumor of the retroperitoneum: A Case Report Yana Kamko
7	Surgical treatment	Laparoscopic Hysterectomy without Uterine Manipulator. Presenting our technique and data of more than 2.000 cases. Dimitrios Zygouris
8	Surgical treatment	Laparoscopic sentinel lymph node (SLN) mapping in endometrial cancer using ICG and NIR technology, presenting our experience and the follow up data. Dimitrios Zygouris
9	Surgical treatment	Update on longterm follow up in patients with cervical cancer that underwent Laparoscopic radical Hysterectomy without uterine manipulator. Dimitrios Zygouris
10	Surgical treatment	Pelvic exenteration in gynecologic cancer: complications and oncological outcome. Dimitrios Zygouris
11	Diagnostics and staging	Clinicopathological features of endometrial cancer in a high-incidence eastern European population: seven-year experience from Ukraine Kateryna Kharchenko
12	Surgical treatment	Surgical features of endometrial cancer in a high-incidence eastern European population: seven-year experience from Ukraine Kateryna Kharchenko
13	Surgical treatment	Our experience of laparoscopic surgery in treatment of the early cervical cancer patients. Case series study and 5-year survival results. Vladyslav Sukhin

SAGO FINAL 11

14	Systemic treatment	Adverse Events Associated with Checkpoint Inhibitor Therapy (± Tyrosine Kinase Inhibitor) in Elderly and Frail Patients with Endometrial Cancer: A Case Series Martina Romanová
15	Systemic treatment	Experience with trastuzumab deruxtecan (T-DXd) in Slovenian cohort of patients with relapsed chemoresistant gynecological cancers Brigita Gregorič



LIST OF RECOMMENDED RESTAURANTS **CLOSE TO THE VENUE**

ACROSS THE STREET

Vietnamese Restaurant Đũa

Vietnamese Type:

Description: authentic Vietnamese cuisine, casual

setting

Price range: \$\$

Studentská 529, Praha 6 Address: Distance: ~5 min (opposite hotel)

Jídelna 17

Important: open to the public only after 13:00 before that, it serves exclusively employees of the building.

Type: Modern Czech Canteen & Café **Description:** A modern eatery offering fresh

> homemade cakes, yogurts, classic breakfast favorites in the morning, and a diverse lunch menu featuring

Czech and global dishes

Price range: \$

Address: Evropská 2690/17, Praha 6

(PPF Gate building)

~2 min (next to the hotel Diplomat) Distance:

Website: www.jidelna17.cz

CZECH CUISINE & PUBS

Kulaťák

Type: Czech Gastropub

Description: classic Czech dishes, tank Pilsner

Urquell, lively atmosphere

Price range: \$\$

Address: Vítězné náměstí 820/12, Praha 6

Distance: ~10 min

Website: www.kulatak.cz

Budvarka Dejvice

Brewpub (Budvar) Type:

Description: Budvar beers, classic Czech pub meals

Price range: \$\$

Address: Wuchterlova 336/22, Praha 6

Distance:

Website: www.budvarkadejvice.cz

Jídlovice

Type: Czech Canteen-Style Bistro

Description: affordable, generous portions of

Czech and international dishes

Price range: \$

Address: Wuchterlova 1608/10, Praha 6

Distance: ~11-12 min Website: www.jidlovice.cz

U veverkv

Traditional Czech Pub Type:

Description: tank Plzeň beer, hearty Czech classics

(goulash, dumplings)

Price range: \$\$

Address: Eliášova 324/14, 160 00 Praha 6

Distance: ~15 min

Website: www.uveverky.com

SAGO PROGRAM

INTERNATIONAL / WORLD FLAVORS

Pizzeria Grosseto Dejvice

Type: Italian Pizzeria & Ristorante

Description: renowned pizzas from wood oven,

pasta, risotto; cozy atmosphere

Price range: \$\$-\$\$\$

Address: Jugoslávských Partyzánů 8, Praha 6

Distance: ~10-12 min

Website: www.grosseto.cz

La Paisanita Dejvice

Type: Argentinian Bistro

Description: empanadas, provoleta, alfajores,

vegan options

Price range: \$\$

Address: Kyjevská 341/1, Praha 6

Distance: ~10-12 min

Website: www.lapaisanita.cz

Tonkin Restaurant Dejvice

Type: Vietnamese & Thai

Description: fresh Asian fusion, weekly lunch menu,

dine-in or takeaway

Price range: \$\$

Address: Na Hutích 661/9, Praha 6

Distance: ~10 min

Website: www.tonkin-dejvice.cz

HEALTHY / VEGETARIAN

Country Life Dejvice

Type: Vegan / Organic Self-Service

Description: salad bar, daily vegan menu, soups,

fresh juices

Price range: \$-\$\$

Address: Československé Armády 30, Praha 6

Distance: ~5–6 min

Website: www.countrylife.cz

Bistro Šodó

Type: Café / Bistro

Description: coffee, pastries, light meals, relaxed

atmosphere

Price range: \$-\$\$

Address: Wuchterlova 1, Praha 6

Distance: ~5-7 min

Website: www.pridejsisodo.cz

Vejce Dejvice

Type: Brunch Café

Description: all-day breakfast (eggs benedict,

pancakes, cakes) plus lunch & dinner

Price range: \$\$

Address: Československé Armády 33, Praha 6

Distance: ~5 min

Website: www.vejcedejvice.cz

FAST-FOOD / QUICK BITES

Burrito Loco Dejvice

Type: Mexican Fast-Food

Description: burritos, tacos, nachos, quick and

casual

Price range: \$

Address: Dejvická 188/6, Praha 6

Distance: ~17 min

Website: www.burritoloco.cz

Bageterie Boulevard Dejvice

Type: Czech Fast-Food Chain

Description: baguettes, soups, salads, seasonal

menu

Price range: \$-\$\$

Address: Vítězné náměstí 14, Praha 6

Distance: ~10 - 12 min www.bb.cz

KFC Dejvice

Type: International Fast-Food

Description: fried chicken, wraps, buckets, salads,

desserts

Price range: \$-\$\$

Address: Vítězné náměstí 576/1, Praha 6

Distance: ~8 min **Website:** www.kfc.cz



Your partner in gynecologic oncology





SHE IS **RESILIENT**SHE IS **READY**SHE IS **HERE**

Přípravek **ELAHERE** je indikován jako monoterapie k léčbě dospělých pacientek s high grade serózním epiteliálním karcinomem ovaria, tubárním karcinomem nebo primárním karcinomem peritonea s pozitivitou folátového receptoru alfa a rezistencí k léčbě na bázi platiny, které podstoupily jeden až tři předchozí režimy systémové léčby.¹



Přípravek ELAHERE je první a jediná schválená cílená terapie, která ve srovnání s chemoterapií přináší významné zlepšení přežití bez progrese a celkového přežití u dospělých pacientek s FRα pozitivním ovariálním karcinomem, které jsou rezistentní vůči chemoterapii založené na platině.^{1,2†}

VÝZNAMNÉ ZLEPŠENÍ PŘEŽITÍ BEZ PROGRESE vs. CHEMOTERAPIE^{1,2†}

Medián PFS.

primární endpoint: 5,62 měsíce vs. 3,98 měsíce, p < 0,0001

ZLEPŠENÍ CELKOVÉHO PŘEŽITÍ vs. CHEMOTERAPIE^{1,2†}

Medián OS.

sekundární endpoint: 16,46 měsíce vs. 12,75 měsíce, p = 0,0046

ZVLÁDNUTELNÝ BEZPEČNOSTNÍ PROFIL^{1,2‡}

Oční nežádoucí účinky byly většinou reversibilní, s úplným či částečným odezněním

FRα = folátový receptor alfa; OS = celkové přežití; PFS = přežití bez progrese

Reference: 1. Souhrn údajů o přípravku Elahere (datum poslední revize 08/2025). 2. Moore KN, Angelergues A, Konecny GE, et al; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162-2174. doi:10.1056/ NEJMoa2309169.



[†] Na základě výsledků multicentrické, nezaslepené, randomizované studie fáze 3, hodnotící přípravek ELAHERE (n = 227) ve srovnání se standardní, zkoušejícím zvolené chemoterapii (n = 226). Onemocnění rezistentní na chemoterapii na bázi platiny bylo definováno jako epiteliální high-grade serózní ovariální karcinom s recidivou v průběhu předchozí terapie nebo v intervalu 6 měsíců po poslední dávce u pacientek se dvěma nebo třemi předchozími liniemi chemoterapie založené na platině nebo s progresí mezi 3. a 6. měsícem u pacientek, které absolvovaly jednu předchozí linii chemoterapie založené na platině. Pozitivita exprese FRα byla definována jako ≥ 75 % životaschopných nádorových buněk s intenzitou barvení membrány ≥ 2+. Primárním cílem hodnocení byl medián PFS podle hodnocení zkoušejícího (5,62 měsíce vs. 3,98 měsíce, p < 0,0001). Klíčovým sekundárním cílem hodnocení byl medián OS (16,46 měsíce vs. 12,75 měsíce, p = 0,0046).²
† Nejčastějšími nežádoucími účinky jakéhokoli stupně při léčbě přípravkem ELAHERE byly rozmazané vidění (43 %), nevolnost (41 %), průjem (39 %), únava (35 %), bolest břicha (30 %), keratopatie (29 %), suché oko (27 %), zácpa (26 %), zvracení (23 %), snížená chuť k jídlu (22 %), periferní neuropatie (20 %), bolest hlavy (19 %), astenie (18 %), zvýšení AST (16 %) a artralgie (16 %).¹





FURTHER PERSPECTIVES in the Treatment of Oncological Diseases.¹

Reference: Keytruda 25 mg SmPC available on www.sukl.cz.





STATE OF THE ART IN GYNECOLOGIC ONCOLOGY

